¿Profilaxis con Cloroquina y/o Hidroxicloroquina para COVID-19?
Barra lateral del artículo
Contenido principal del artículo
Resumen
Efectuando una búsqueda en los meta buscadores de Pubmed, HINARI y Scielo con los términos “prophylaxis” “Hydroxychloroquine” y “COVID-19” enlazados por el operador booleano AND, de igual forma se utilizaron los términos “Chloroquine” “prophylaxis” y “COVID-19”, enlazados por el operador booleano AND. La búsqueda con el término “Hydroxychloroquine” no arrojó ningún resultado, mientras que la búsqueda con el término “Chloroquine” arrojó dos publicaciones en HINARI, de las cuales se descartó una por no mencionar el uso de la cloroquina (o la hidroxicloroquina) como alternativa terapéutica. Con respecto al uso como profilaxis para prevenir la infección por SARS-CoV-2 con CQ o HCQ, no contamos con evidencia que permita extrapolar o tan siquiera recomendar un esquema con tales fines.
Descargas
Detalles del artículo
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
INVESTIGATIO es de acceso abierto y el contenido está disponible de manera gratuita a través de su sitio web: http://revistas.uees.edu.ec/index.php/IRR/.
Para reforzar nuestra política de acceso abierto, la revista INVESTIGATIO se publica bajo una licencia Creative Commons Reconocimiento-No Comercial 4.0 Internacional (CC-BY-NC 4.0), la cual permite compartir (copiar y redistribuir el material en cualquier medio o formato) y adaptar (remezclar, transformar y crear a partir del material), bajo la condición de que se den los créditos correspondientes y no se haga uso comercial de los materiales.
Citas
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., & Fan, G. et al. (2020). A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine. doi: 10.1056/nejmoa2001282
Cennimo, D. (2020). Coronavirus Disease 2019 (COVID-19) Treatment & Management: Approach Considerations, Medical Care, Prevention. Retrieved 1 April 2020, from https://emedicine.medscape.com/article/2500114-treatment
Centers for Disease Control and Prevention. (2020). Coronavirus Disease 2019 (COVID-19). Retrieved 1 April 2020, from https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html
Chang, R., & Sun, W. (2020). Repositioning Chloroquine as Ideal Antiviral Prophylactic against COVID-19 - Time is Now. doi: 10.20944/preprints202003.0279.v1
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., & Han, Y. et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395(10223), 507-513. doi: 10.1016/s0140-6736(20)30211-7
Coello, C. (2020). Expertos advierten sobre el uso de hidroxicloroquina como profilaxis en personal sanitario. Edición Médica. Retrieved from https://www.edicionmedica.ec/secciones/profesionales/expertos-advierten-sobre-el-uso-hidroxicloroquina-como-profilaxis-en-personal-sanitario-95544
Colson, P., Rolain, J., Lagier, J., Brouqui, P., & Raoult, D. (2020). Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. International Journal of Antimicrobial Agents, 105932. doi: 10.1016/j.ijantimicag.2020.105932
CSSE, & JHU. (2020). Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Retrieved 1 April 2020, from https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.
Delvecchio, R., Higa, L., Pezzuto, P., Valadão, A., Garcez, P., & Monteiro, F. et al. (2016). Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models. Viruses, 8(12), 322. doi: 10.3390/v8120322
Gautret, P., Lagier, J., Parola, P., Hoang, V., Meddeb, L., & Mailhe, M. et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal Of Antimicrobial Agents, 105949. doi: 10.1016/j.ijantimicag.2020.105949
Gorbalenya, A., Baker, S., Baric, R., de Groot, R., Drosten, C., & Gulyaeva, A. et al. (2020). Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. doi: 10.1101/2020.02.07.937862
Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., & Hripcsak, G. et al. (2020). Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal Of Medicine, 1-8
Kearney, J. (2020). Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review. doi: 10.20944/preprints202003.0275.v1
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Ranst, M. (2004). In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochemical And Biophysical Research Communications, 323(1), 264-268. doi: 10.1016/j.bbrc.2004.08.085
Kim, J., Chung, Y., Jo, H., Lee, N., Kim, M., & Woo, S. et al. (2020). Identification of Coronavirus Isolated from a Patient in Korea with COVID-19. Osong Public Health And Research Perspectives, 11(1), 3-7. doi: 10.24171/j.phrp.2020.11.1.02
Lam, T., Shum, M., Zhu, H., Tong, Y., Ni, X., & Liao, Y. et al. (2020). Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature. doi: 10.1038/s41586-020-2169-0
Lau, S., Lau, C., Chan, K., Li, C., Chen, H., & Jin, D. et al. (2013). Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. Journal Of General Virology, 94(12), 2679-2690. doi: 10.1099/vir.0.055533-0
Magagnoli, J., Narendran, S., Pereira, F., Cummings, T., Hardin, J., Sutton, S., & Ambati, J. (2020). Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. doi: 10.1101/2020.04.16.20065920
Ministerio de Sanidad. (2020). Manejo clínico del COVID-19: tratamiento médico. España: Ministerio de Sanidad.
Mitjà, O., & Clotet, B. (2020). Use of antiviral drugs to reduce COVID-19 transmission. The Lancet Global Health. doi: 10.1016/s2214-109x(20)30114-5
Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia (2020). Zhonghua Jie He He Hu Xi Za Zhi. Expert Consensus on Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia. Chinese Journal of Tuberculosis and Respiratory Diseases, 43(3), 185–188. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.009
PubChem. (2020). Chloroquine phosphate: Compound Summary. Retrieved 1 April 2020, from https://pubchem.ncbi.nlm.nih.gov/compound/Chloroquine-phosphate
Savarino, A., Boelaert, J., Cassone, A., Majori, G., & Cauda, R. (2003). Effects of chloroquine on viral infections: an old drug against today's diseases. The Lancet Infectious Diseases, 3(11), 722-727. doi: 10.1016/s1473-3099(03)00806-5
Sheahan, T., Sims, A., Leist, S., Schäfer, A., Won, J., & Brown, A. et al. (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications, 11(1). doi: 10.1038/s41467-019-13940-6
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., & Xu, M. et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269-271. doi: 10.1038/s41422-020-0282-0
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., & Niu, P. et al. (2020). In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases. doi: 10.1093/cid/ciaa237
Yu, B., Wang, D., & Li, C. (2020). Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. doi: 10.1101/2020.04.27.20073379
Zhang, L., & Liu, Y. (2020). Potential interventions for novel coronavirus in China: A systematic review. Journal of Medical Virology, 92(5), 479-490. doi: 10.1002/jmv.25707
Zhang, T., Wu, Q., & Zhang, Z. (2020). Probable Pangolin Origin of 2019-nCoV Associated with Outbreak of COVID-19. Current-Biology-D-20-00299. Available at SSRN: https://ssrn.com/abstract=3542586. doi: 10.2139/ssrn.3542586.
Zhou, D., Dai, S., & Tong, Q. (2020). COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. Journal Of Antimicrobial Chemotherapy. doi: 10.1093/jac/dkaa114
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., & Song, J. et al. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal Of Medicine, 382(8), 727-733. doi: 10.1056/nejmoa2001017